Israeli scientists find a promising potential treatment for pancreatic cancer

(Natural News) Pancreatic cancer is one of the most daunting varieties of the disease, with very few people surviving beyond five years after their diagnosis. With few symptoms, most patients aren’t diagnosed until they’ve already reached the metastatic stage. It’s the fourth leading cause of cancer deaths and the 12th most common type of cancer...
Source: - Category: Consumer Health News Source Type: news

Related Links:

The majority of doctors will tell you that there is nothing you can do to reverse fatty liver and that health problems such as cirrhosis and liver failure may be in your future that they will address with the awful “solution” of liver transplant. The truth is the opposite: fatty liver is easily and readily reversible in virtually everybody, provided you take action before irreversible changes take place and are given the right information and tools. In this video, I discuss the three basic phenomena that drive fat deposition, liver damage, and inflammation that lead to this condition: Carbohydrate consumption ...
Source: Wheat Belly Blog - Category: Cardiology Authors: Tags: Open bowel flora carbohydrates carbs Inflammation NAFLD nash triglycerides undoctored wheat belly Source Type: blogs
When the patriarch of a Boston-area family was diagnosed with stage 3 pancreatic cancer, the family was told he needed to start treatment immediately.
Source: - Health - Category: Consumer Health News Source Type: news
Targeted therapy using monoclonal antibodies conjugated to toxins is gaining space in the treatment of cancer. Here, we report the anti-tumor effect of a new antibody drug conjugate (ADC) delivering a HDAC inhibitor to ErbB2+ solid tumors. Trastuzumab was partially reduced with tris [2-carboxyethyl] phosphine (TCEP) and conjugated to ST7464AA1, the active form of the prodrug HDAC inhibitor ST7612AA1, through a maleimide-thiol linker to obtain the Antibody Drug Conjugate (ADC) ST8176AA1. The average drug/antibody ratio (DAR) was 4.5 as measured by hydrophobic interaction chromatography (HIC). Binding of ST8176AA1 to ErbB2 r...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
sin Okada Yamada Dapagliflozin, empagliflozin, tofogliflozin, selective inhibitors of sodium-glucose cotransporter 2 (SGLT2), is used clinically to reduce circulation glucose levels in patients with type 2 diabetes mellitus by blocking the reabsorption of glucose by the kidneys. Dapagliflozin is metabolized and inactivated by UGT1A9. Empagliflozin is metabolized and inactivated by UGT1A9 and by other related isoforms UGT2B7, UGT1A3, and UGT1A8. Tofogliflozin is metabolized and inactivated by five different enzymes CYP2C18, CYP3A4, CYP3A5, CYP4A11, and CYP4F3. Dapagliflozin treatment of HCT116 cells, which express...
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
The objective of this study was to further explore the function of PTEN expression in human pancreatic cancer. The expression of PTEN has been dominant in various human cancers including pancreatic cancer when compared with their matched normal tissues. The pancreatic cancer cells have been divided into PTEN blockade-susceptible and PTEN blockade-impassible groups dependent on targeting PTEN by altering intracellular signaling. The expression of PTEN has led to varying clinical outcomes of pancreatic cancer based on GEO Series (GSE) data analysis and Liptak’s z analysis. Differential dependency to PTEN blockade h...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
British Journal of Cancer, Published online: 23 January 2020; doi:10.1038/s41416-019-0704-2Preoperative detection of KRAS G12D mutation in ctDNA is a powerful predictor for early recurrence of resectable PDAC patients
Source: British Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
Cell Death &Disease, Published online: 23 January 2020; doi:10.1038/s41419-020-2262-1Correction: Schwann cells support oncogenic potential of pancreatic cancer cells through TGFβ signaling
Source: Cell death and disease - Category: Internal Medicine Authors: Source Type: research
Source: Journal of Gastrointestinal Cancer - Category: Cancer & Oncology Source Type: research
ConclusionThe results are encouraging, suggesting that SBRT has a significant role in the management of these patients and further studies will be necessary to prove these findings.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
More News: Cancer | Cancer & Oncology | Health | Israel Health | Pancreas | Pancreatic Cancer